About Oncology Trials

The St. Luke’s Oncology Clinical Trials team provides support to our clinical investigators on all activities related to the successful conduct of clinical trials and research from protocol inception through closeout, such as patient recruitment, clinical coordination, data and regulatory management, and financial and contract management. Our staff provides patients with the most up-to-date information on treatments that are available to them, as we believe in putting the patient first by ensuring that we present all available treatment options, including participation in a clinical trial.

The St. Luke’s Oncology Clinical Trials team offers studies that are sponsored by industry pharmaceutical companies, government sponsored studies through NCI’s National Clinical Trials Network (NCTN) such as ECOG-ACRIN and NRG, as well as homegrown investigator-initiated trials (IITs), some of which are multi-site with St. Luke’s serving as the lead coordinating center. This robust clinical trial portfolio consists of numerous treatment trials, and trials that are exclusive to St. Luke’s, bringing innovative therapies to the Lehigh Valley and surrounding area. We also offer clinical trials which consist of newly FDA-approved drugs, as well as expanded access trials (awaiting FDA approval), providing the latest and greatest therapies, as well as unapproved therapies, to our patients.

We are dedicated to growing our clinical trials portfolio and identifying gaps in treatment options through the use of Disease Management meetings and disease-specific tumor boards. This allows us the ability to offer our patients treatment options for various diseases that may not have been previously available, as well as offer innovative treatments to patients who are waiting for new treatment options and/or their next line of therapy without delay.

The St. Luke’s Oncology Clinical Trials team offers patients a variety of clinical research trials, quality service, education, and support across the continuum of care.